These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 17900874)

  • 1. Introduction: historical perspective and development of amoxicillin/clavulanate.
    Geddes AM; Klugman KP; Rolinson GN
    Int J Antimicrob Agents; 2007 Dec; 30 Suppl 2():S109-12. PubMed ID: 17900874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical development and launch of amoxicillin/clavulanate for the treatment of a range of community-acquired infections.
    Ball P
    Int J Antimicrob Agents; 2007 Dec; 30 Suppl 2():S113-7. PubMed ID: 17997283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conclusions: the future of antimicrobial therapy - Augmentin and beyond.
    Ball P
    Int J Antimicrob Agents; 2007 Dec; 30 Suppl 2():S139-41. PubMed ID: 18029150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.
    White AR; Kaye C; Poupard J; Pypstra R; Woodnutt G; Wynne B
    J Antimicrob Chemother; 2004 Jan; 53 Suppl 1():i3-20. PubMed ID: 14726431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a twice daily dosing regimen of amoxicillin/clavulanate.
    Bax R
    Int J Antimicrob Agents; 2007 Dec; 30 Suppl 2():S118-21. PubMed ID: 17983732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The development of pharmacokinetically enhanced amoxicillin/clavulanate for the management of respiratory tract infections in adults.
    File TM
    Int J Antimicrob Agents; 2007 Dec; 30 Suppl 2():S131-4. PubMed ID: 18029151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended release amoxicillin/clavulanate: optimizing a product for respiratory infections based on pharmacodynamic principles.
    Jacobs MR
    Expert Rev Anti Infect Ther; 2005 Jun; 3(3):353-60. PubMed ID: 15954852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmentin treatment of bacterial infections in hospitalised patients.
    Ellis-Pegler RB; Lang SD; Downey DJ; Anderson MP
    N Z Med J; 1982 Aug; 95(713):542-5. PubMed ID: 6752781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta-lactam antibiotics: newer formulations and newer agents.
    Martin SI; Kaye KM
    Infect Dis Clin North Am; 2004 Sep; 18(3):603-19, ix. PubMed ID: 15308278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The history and background of Augmentin.
    Rolinson GN
    S Afr Med J; 1982 Jul; 62(5 Spec No):3A-4A. PubMed ID: 6979804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Rodríguez-Baño J; Alcalá JC; Cisneros JM; Grill F; Oliver A; Horcajada JP; Tórtola T; Mirelis B; Navarro G; Cuenca M; Esteve M; Peña C; Llanos AC; Cantón R; Pascual A
    Arch Intern Med; 2008 Sep; 168(17):1897-902. PubMed ID: 18809817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combating resistance: application of the emerging science of pharmacokinetics and pharmacodynamics.
    Jacobs MR
    Int J Antimicrob Agents; 2007 Dec; 30 Suppl 2():S122-6. PubMed ID: 17936592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Betalactam antibiotics combined with bectalactamases inhibitors. Amoxicillin-sulbactam].
    Barcelona L; Marín M; Stamboulian D
    Medicina (B Aires); 2008; 68(1):65-74. PubMed ID: 18416324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modified Antibiotic Adjuvant Ratios Can Slow and Steer the Evolution of Resistance: Co-amoxiclav as a Case Study.
    Allen RC; Brown SP
    mBio; 2019 Sep; 10(5):. PubMed ID: 31530673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of cefditoren pivoxil and amoxicillin/clavulanate in the treatment of pediatric patients with acute bacterial rhinosinusitis in Thailand: a randomized, investigator-blinded, controlled trial.
    Poachanukoon O; Kitcharoensakkul M
    Clin Ther; 2008 Oct; 30(10):1870-9. PubMed ID: 19014842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of the antimicrobial activity of clavulanate.
    Finlay J; Miller L; Poupard JA
    J Antimicrob Chemother; 2003 Jul; 52(1):18-23. PubMed ID: 12775671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of the spectrum and potency of orally administered cephalosporins and amoxicillin/clavulanate.
    Sader HS; Jacobs MR; Fritsche TR
    Diagn Microbiol Infect Dis; 2007 Mar; 57(3 Suppl):5S-12S. PubMed ID: 17292577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of cloned inhibitor-resistant TEM beta-lactamases on the susceptibility of Haemophilus influenzae to amoxicillin/clavulanate.
    Tristram SG; Burdach JG
    J Antimicrob Chemother; 2007 Nov; 60(5):1151-4. PubMed ID: 17827143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetically enhanced amoxicillin/clavulanate (2,000/125 mg) in acute bacterial rhinosinusitis caused by Streptococcus pneumoniae, including penicillin-resistant strains.
    Anon JB; Ferguson B; Twynholm M; Wynne B; Berkowitz E; Poole MD
    Ear Nose Throat J; 2006 Aug; 85(8):500, 502, 504 passim. PubMed ID: 16999056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of different resistance traits on the competitive growth of Haemophilus influenzae in antibiotic-free medium and selection of resistant populations by different {beta}-lactams: an in vitro pharmacodynamic approach.
    González N; Aguilar L; Alou L; Giménez MJ; Sevillano D; Torrico M; Cafini F; Coronel P; Prieto J
    J Antimicrob Chemother; 2009 Jun; 63(6):1215-22. PubMed ID: 19307171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.